Ziopharm’s Future Uncertain After Poor PICASSO Results
This article was originally published in Pharmaceutical Approvals Monthly
The oncology company ends development of its Phase III candidate in soft tissue sarcoma after progression-free survival data fail to live up to earlier expectations. The company will now refocus on its mid-stage pipeline.
You may also be interested in...
A death was reported in the company's early-stage gene therapy trial. It has not been determined yet whether the death was related to the drug and what the next steps for the company are.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.